Cargando…
Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?
Heart failure with preserved ejection fraction, i.e. HFpEF, is highly prevalent in ageing populations, accounting for more than 50 % of all cases of heart failure in Western societies, and is closely associated with comorbidities such as obesity, diabetes and arterial hypertension. However, all larg...
Autores principales: | Kovács, Á., Alogna, A., Post, H., Hamdani, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796050/ https://www.ncbi.nlm.nih.gov/pubmed/26924822 http://dx.doi.org/10.1007/s12471-016-0814-x |
Ejemplares similares
-
Heart Failure With Preserved Ejection Fraction and Obesity: Syndrome of cGMP-PKG Deficiency in Post-Menopausal Women
por: Sinha, Arjun, et al.
Publicado: (2020) -
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2013) -
The role of cGMP and PKG in cardioprotection
por: Downey, James M, et al.
Publicado: (2009) -
Role of cGMP/PKG in fat tissue
por: Pfeifer, Alexander
Publicado: (2011) -
Cyclic GMP and PKG Signaling in Heart Failure
por: Numata, Genri, et al.
Publicado: (2022)